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Abstract
Background: Dengue is a major mosquito-borne disease currently with no effective antiviral or vaccine available.
Effort to find antivirals for it has focused on bioflavonoids, a plant-derived polyphenolic compounds with many
potential health benefits. In the present study, antiviral activity of four types of bioflavonoid against dengue virus
type -2 (DENV-2) in Vero cell was evaluated. Anti-dengue activity of these compounds was determined at different
stages of DENV-2 infection and replication cycle. DENV replication was measured by Foci Forming Unit Reduction
Assay (FFURA) and quantitative RT-PCR. Selectivity Index value (SI) was determined as the ratio of cytotoxic
concentration 50 (CC50) to inhibitory concentration 50 (IC50) for each compound.
Results: The half maximal inhibitory concentration (IC50) of quercetin against dengue virus was 35.7 μg mL
-1 when
it was used after virus adsorption to the cells. The IC50 decreased to 28.9 μg mL
-1 when the cells were treated
continuously for 5 h before virus infection and up to 4 days post-infection. The SI values for quercetin were 7.07
and 8.74 μg mL-1, respectively, the highest compared to all bioflavonoids studied. Naringin only exhibited anti-
adsorption effects against DENV-2 with IC50 = 168.2 μg mL
-1 and its related SI was 1.3. Daidzein showed a weak
anti-dengue activity with IC50 = 142.6 μg mL
-1 when the DENV-2 infected cells were treated after virus adsorption.
The SI value for this compound was 1.03. Hesperetin did not exhibit any antiviral activity against DENV-2. The
findings obtained from Foci Forming Unit Reduction Assay (FFURA) were corroborated by findings of the qRT-PCR
assays. Quercetin and daidzein (50 μg mL-1) reduced DENV-2 RNA levels by 67% and 25%, respectively. There was
no significant inhibition of DENV-2 RNA levels with naringin and hesperetin.
Conclusion: Results from the study suggest that only quercetin demonstrated significant anti-DENV-2 inhibitory
activities. Other bioflavonoids, including daidzein, naringin and hesperetin showed minimal to no significant
inhibition of DENV-2 virus replication. These findings, together with those previously reported suggest that select
group of bioflavonoids including quercetin and fisetin, exhibited significant inhibitory activities against dengue
virus. This group of flavonoids, flavonol, could be investigated further to discover the common mechanisms of
inhibition of dengue virus replication.
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Background
Dengue virus (DENV) is a member of the genus flavi-
virus of the Flaviviridae family. It is a significant human
pathogen which causes a wide spectrum of clinical ill-
nesses ranging from a silent or mild febrile infection,
self-limited dengue fever (DF) to the severe dengue
hemorrhagic fever (DHF) and dengue shock syndrome
(DSS). There are four dengue virus genotypes, DENV-1,
DENV-2, DENV-3 and DENV-4 which are transmitted
to humans mainly by two species of mosquitoes, Aedes
agypti and Aedes Albopictus [1]. All four DENV can
cause dengue. To date there are no effective vaccine or
antiviral treatment for dengue. Dengue patients are
usually supportively-treated until they recover without
any specific treatment measures. Several studies have
shown that the level of viremia correlates with the
severity of disease with high viremia often seen in severe
dengue. Hence, antivirals that can reduce the level of
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viremia or the viremic phase could possibly reduce the
severity of dengue.
Plants and plant’s derived compounds remain an
important source for the discovery and the development
of new antiviral drugs because of their expected low
side effects and their high accessibility in the nature
[2-4]. There have been numerous reports on the anti-
viral activity of various phytochemicals against dengue
viruses and these include various flavonoids [5-8]. Flavo-
noids are basically low molecular weight phenolic com-
pounds found widely in different kinds of plants.
Different types of flavonoids can be found in fruits,
roots, nuts, seeds, bark, steams and flowers of plants.
These include quercetin which can be found in some
foods and fruits such as green and black tea, apple,
onion, citrus, tomato and some other plants [9,10]. Anti-
viral activities of various other flavonoids have also been
reported against some viruses including human cytome-
galovirus (HCMV), HSV-1, HSV-2 and some types of
human adenoviruses [11-13].
In the present study, we are interested to examine the
anti-dengue virus properties of quercetin, hesperetin,
naringin and daidzein. Hesperetin is a flavonone and its
glycoside form, hesperidin is water soluble and it could
be found in various citrus fruits. After ingestion of
hesperidin, its sugar moiety is released from the back-
bone of this compound and the aglycone form known
as hesperetin can be released. In vitro antiviral activities
of hesperetin have been reported against some RNA
viruses [14-16]. Naringin on the other hand, is a flavo-
none glycoside found abundantly in grapefruit juice.
Antiviral activity of naringin were reported against
HSV-1 and HSV-2 but this finding remains controver-
sial [12,17]. Daidzein is an isoflavone found in soybeans
and its antiviral activity against influenza viruses has
been reported [18]. Currently, there is no published data
on the possible anti-dengue virus activities of quercetin,
hesperetin, naringin and daidzein. Therefore, in this
study we evaluated these compounds activities on
DENV-2 (NGC strain) replication in cell culture system.
The effects of each compound were evaluated against
different stages of dengue virus replication including
virus adsorption, intracellular replication and direct vir-
ucidal activities.
Methods
Bioflavonoids
Four different types of bioflavonoid, quercetin, naringin,
hesperetin (Sigma-Aldrich, St. Louis, MO, USA) and
daidzein (Indofine Chemical Co. Inc., Hillsborough, NJ,
USA) were evaluated for their potential activities against
dengue virus replication. Dimethyl sulfoxide (DMSO)
(Sigma-Aldrich, St. Louis, MO, USA) was used to dis-
solve the lyophilized form of compounds and prepared
stock solutions (20 mg mL-1) were stored at -20 C.
Stock solution was diluted using cell culture medium
and sterilized by a syringe filter with 0.2 μm pore size
(Millipore, MA, USA) right before each experiment.
Cells and virus
C6/36 mosquito cell line derived from Aedes albopictus
and Vero (African green monkey kidney) cell line were
used in this study. Both cell lines were maintained and
propagated in Eagle’s Minimum Essential Medium
(EMEM) (Gibco, NY, USA) containing 10% fetal bovine
serum (Gibco, NY, USA). Cultured C6/36 and Vero
cells were incubated at 28 C and 37 C, respectively in
5% CO2 humidified chamber. At the time of virus pro-
pagation, serum concentration was reduced to 2%. Den-
gue virus type-2 (DENV-2) New Guinea C strain (NGC)
was propagated using C6/36 cell line and harvested after
CPE presentation on day seven post-infection. After
titration, viral stock was stored at -70 C. Cell lines and
virus were provided by Virology laboratory of the Tropi-
cal Infectious Disease Research and Education Center,
Faculty of Medicine, University of Malaya (Kuala Lum-
pur, Malaysia).
In vitro cytotoxicity assay
MTT assay was performed following the manufacturer’s
instructions (Promega, WI, USA). Briefly, confluent
Vero cells in 96-well cell culture microplates were trea-
ted with different concentrations of each compound in
triplicate. The treated cells were incubated for four days
at 37 C followed by the addition of 15 μl of MTT solu-
tion to each well. The microplate was incubated at 37 C
for 4 h. Then, 100 μl of the solubilisation/stopping solu-
tion was added to each well. The optical density (OD)
of wells was measured at 570 using 96-well plate reader
(TECAN, Mannendorf, Switzerland). Dose-response
curves were plotted using Graph Pad Prism 5 (Graph
Pad Software Inc., San Diego, CA).
Pretreatment of cells with bioflavonoids
In order to determine the prophylactic anti-dengue
activity of compounds, different concentrations of com-
pounds were added to the Vero monolayer cells in tri-
plicate at different times, 5 h before virus infection.
After 5 h of pre-infection treatment, the cells were
washed twice with sterile PBS and then 200 FFU of
DENV-2 was inoculated to the cells and incubated at 37
C for 1 h. To determine the effects of continuous treat-
ment, different concentrations of each compound were
added to the Vero cells, 5 h pre-infection and continu-
ously for 4 days post-infection.
In a separate experiment, antiviral activity of com-
pounds against intracellular replication of DENV-2 was
performed by inoculation of 200 FFU of virus to each
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well in triplicate. After adsorption of virus to the cells
for 1 h at 37 C, the cells were washed with PBS to elim-
inate the unabsorbed viruses. Then, different concentra-
tions of each compound were added to the cells,
followed by 4 days of incubation at 37 C. DENV RNA
was then quantified using quantitative RT-PCR. In
another experiment, Vero cells at 80% confluency were
infected with 200 FFU of DENV-2 in the presence or
absence of different concentrations of each compound.
The microplate was kept at 37 C for 1 h for virus
adsorption. Then the cells were washed two times by
sterile PBS and incubated at 37 C for four days.
Direct virucidal effects of the bioflavonoids were
investigated by incubating DENV-2 suspension contain-
ing 200 FFU with an equal volume of the different con-
centrations of each compound for 2 h at 37 C. Then,
Vero cells were infected with the treated viral suspen-
sion in triplicate. After 1 h adsorption at 37 C, cells
were washed twice with PBS in order to remove unab-
sorbed viruses. Then the microplate was incubated at 37
C for 4 days.
Antiviral activity assay
Antiviral activities of the tested compounds were evalu-
ated by measuring the reduction in number of viral foci.
Briefly, confluent monolayers of Vero cells were pre-
pared in 24 wells cell culture microplate. Then the
infected cells treated using different procedures
described above were overlaid with 1.5% of Carboxy
Methyl Cellulose (CMC) (Sigma-Aldrich, St. Louis, MO,
USA) containing EMEM. Viral foci were visualized
using peroxidase-based foci staining assay four days post
infection [19]. The numbers of DENV-2 foci were
counted using a stereomicroscope and the titer of virus
was expressed as Foci-Forming-Unit (FFU). The percen-
tage of viral foci reduction (RF %) compared with con-
trols was calculated as follows: RF (%) = (C-T) × 100/C.
Where, C is the mean of the number of foci for negative
control well (without compound) and T is the mean of
the number of foci in treated wells. Reduction in the
number of viral foci was further verified using quantita-
tive RT-PCR (qRT-PCR).
Dengue virus quantitative RT-PCR (qRT-PCR)
Quantitative RT-PCR was performed to determine the
effects of bioflavonoids on DENV replication by quanti-
fying DENV-2 genomic RNA copies based on a method
described previously with some modifications [20].
Briefly, intracellular and extracellular DENV-2 RNAs
were harvested from the DENV-infected Vero cells.
Viral RNA was extracted using two types of RNA
extraction kits (QIAamp Viral RNA mini kit and RNeasy
mini kit) (Qiagen, Hilden, Germany). Quantitative RT-
PCR assay was performed by adding 1 μl of extracted
DENV RNA to the SensiMix SYBR green reagent
(Quantace, Watford, United Kingdom) which contained
7.4 μl ddH2O, 10 μl 2X SensiMix One-Step, 0.4 μl 50X
SYBR Green solution, 10 units of RNAse Inhibitor, 50
pmol of forward (DNF) and also reverse (D2R) primers
[21]. All samples were assayed in triplicate. The amplifi-
cations were performed using the DNA Engine Opticon
system (MJ Research/Bio-Rad, Hercules, CA) with the
following thermal conditions: reverse transcription at
50°C for 30 min, initial denaturation at 95°C for 10 min,
followed by 45 cycles of 95°C for 15 sec, 59°C for 30 sec
and 72°C for 30 sec. Melting curve analysis was subse-
quently performed at temperature from 60°C to 98°C to
verify the assay specificity. For absolute quantitation of
the viral RNA, a standard curve was established with a
serially diluted RNA extracted from DENV-2 stock with
known titer.
Statistical analysis
Graph Pad Prism for Windows, version 5 (Graph Pad
Software Inc., San Diego, CA, 2005) was used to deter-
mine the cytotoxic concentration 50 (CC50) and inhibi-
tory concentration 50 (IC50) values of bioflavonoids.
Selectivity Index value (SI) was determined as the ratio
of CC50 to IC50 for each compound.
Results
Cytotoxicity of bioflavonoids
MTT assay was used to determine cytotoxicity of each
bioflavonoid on Vero cells and the CC50 value of each
compound was calculated (Table 1 and Figure 1). Vero
cells were treated by bioflavonoids for 4 days which was
the same duration used for antiviral activity assay.
Results showed that hesperetin with CC50 = 110.3 ±
0.32 μg mL-1 is the most cytotoxic compound for Vero
cells compared to the other tested compounds. Querce-
tin and daidzein showed lower toxicity against Vero
cells at CC50 252.6 ± 0.17 and 147.8 ± 0.31 μg mL
-1,
respectively. Meanwhile, naringin with CC50 = 230.3 ±
0.19 μg mL-1 showed the least cytotoxic effects against
Vero cells. Cells treated with vehicle control, 1% DMSO
did not show any cytotoxicity against Vero cells.
Table 1 Cytotoxicity assays were performed using the
MTT assay method described in text
Flavonoids CC50(μg mL
-1)
Quercetin 252.6 ± 0.17
Daidzein 147.8 ± 0.31
Naringin 230.3 ± 0.19
Hesperetin 110.3 ± 0.32
The CC50 of bioflavonoids were calculated using Graph Pad Prism Version 5
(Graph Pad Software Inc., San Diego, CA.). Results are presented as mean ± SD
of triplicate experiment.
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Antiviral activity of bioflavonoids
Results of Vero cells pre-treatment with the compounds
showed that 50 μg mL-1 of quercetin could decrease the
number of DENV-2 foci by 14% ± 1.5 when compared
to the non-treated cells. However, there was no prophy-
lactic activity against DENV-2 from other compounds
(data not shown). In post-adsorption assay, quercetin
exhibited the most significant antiviral activity against
DENV-2 amongst the bioflavonoids tested with IC50 =
35.7 μg mL-1 (Figure 2a). The SI value for quercetin in
post-adsorption assay was relatively high at 7.07. It was
also demonstrated that the level of DENV-2 specific
RNA production in the presence of 50 μg mL-1 of quer-
cetin decreased by more than 67% ± 1 when compared
to the non-treated infected cells (Figure 2b). Daidzein
showed very weak anti-dengue activity with IC50 = 142.6
μg mL-1 when the infected cells were treated after
DENV-2 adsorption (Figure 2a). Its related SI value was
1.03. The levels of DENV-2 RNA production in the pre-
sence of 50 μg mL-1 of daidzein decreased by only
25.3% ± 0.7 when compared to the non-treated infected
cells (Figure 2b). Naringin and hesperetin did not exhi-
bit any anti-dengue activity when they were used after
adsorption of DENV-2 to the Vero cells (Figure 2).
Although there was no significant direct virucidal
activity against DENV-2 by quercetin, continuous treat-
ment of cells from 5 h before virus infection up to 4
days post-infection exhibited anti-dengue activity with
IC50 = 28.9 μg mL
-1 (Figure 3a). The SI value for
continuous treatment with quercetin was 8.74 and
higher than the SI value (7.07) for post-adsorption assay.
In addition, the level DENV-2 RNA production
decreased by more than 75.7% ± 1.57 when Vero cells
were treated with 50 μg mL-1 of quercetin, 5 h before
virus infection and up to 4 days post infection (Figure
3b). There was no significant change in the antiviral
activity of daidzein when cells were treated continuously
from 5 h before virus infection up to 4 days post infec-
tion comparing to its anti-dengue activity for post-
adsorption treatment (Figure 1). No significant antiviral
activity for naringin and hesperetin was observed for the
continuous treatment against DENV-2 (Figure 2). How-
ever, naringin exhibited anti-adsorption activity when it
was added to the cells at the same time of virus adsorp-
tion. The IC50 value for naringin was 168.2 μg mL
-1 and
its related SI was 1.3 (Figure 3a). There was a reduction
of 25.8% ± 0.76 in DENV-2 RNA production in the pre-
sence of 50 μg mL-1 of naringin (Figure 4a).
The majority of the viral foci in cells treated with 50
μg/ml quercetin appeared smaller, less intensely stained
and more diffused within the focus (Figure 5b), com-
pared to the larger, well-defined and more intensely
stained foci of the untreated cells (Figure 5a). This
observation is consistent with the reduction of the per-
centage of foci and RNA copy number.
Results from the direct virucidal activity evaluation of
each compound showed that there was no extracellular
inhibitory activity against DENV-2 for all the tested
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Figure 1 Cytotoxicity of flavonoids against Vero cells. MTT assay was performed on Vero cells after 96 h treatment with increasing
concentrations of the flavonoids. Results are presented as percentage of cell viability from triplicate assays.
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compounds. Similarly, qRT-PCR analysis showed that
there was no significant decrease in copy number of
DENV-2 RNA following direct treatment of DENV-2
with the different concentrations of each compound
(data not shown).
Discussion
Recent studies have shown that flavonoids such as glab-
ranine and 7-O-Methyle glabranine exhibited significant
antiviral activities against dengue virus. In vitro treat-
ment of infected cells with these flavonoids resulted in
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Figure 2 Anti-viral assay of flavonoids against DENV-2 intracellular replication. Foci forming unit reduction assay (FFURA) was used to
evaluate the in vitro anti-dengue virus activities of flavonoids after viral adsorption (a) and the respective DENV-2 RNA copies were quantified
using qRT-PCR (b). The percentages of foci reduction (% RF) were calculated relative to the untreated controls maintained in parallel. Data from
triplicate assays were plotted using Graph Pad Prism Version 5 (Graph Pad Software Inc., San Diego, CA. USA).
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Figure 3 Anti-viral effects of continuous treatment with flavonoids against DENV-2 replication. Foci forming unit reduction assay (FFURA)
was used to evaluate the in vitro anti-dengue virus activities of the flavonoids. Cells were treated with the flavonoids at 5 h before infection and
continuously treated with fresh flavonoids upto 4 days post infection (a). The respective DENV-2 RNA copy numbers were quantified using qRT-
PCR (b). The percentages of foci reduction (% RF) were obtained by comparing against untreated controls maintained in parallel. Data from
triplicate experiments were plotted using Graph Pad Prism Version 5 (Graph Pad Software Inc., San Diego, CA).
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Figure 4 Anti-adsorption activity of flavonoids against DENV-2. Flavonoids were added directly to virus inocula for 2 h at 37 C. The inocula
were used to infect Vero cell monolayers in 24 wells cell culture microplates. The reduction in foci forming unit was calculated relative to the
controls maintained in parallel (a) and the respective DENV-2 RNA copy numbers were quantified using qRT-PCR (b). Data from triplicate
experiments were plotted using Graph Pad Prism Version 5 (Graph Pad Software Inc., San Diego, CA).
Zandi et al. Virology Journal 2011, 8:560
http://www.virologyj.com/content/8/1/560
Page 7 of 11
the reduction of intracellular replication of dengue virus
by 76.9% and 75% following treatment with 25 μM of
glabranine and 7-O-Methyle glabranine, respectively
[22]. Similarly, other synthetic flavonoid derivatives also
showed antiviral activity in HepG2 cells [23]. Whereas,
pinostrobin was reported to inhibit DENV-2 NS2B/NS3
protease an enzyme important in dengue virus replica-
tion in an in vitro study [24]. These suggest that
 
 
(a)
(b)
Figure 5 Foci size reduction in DENV-infected cell treated with quercetin. Foci forming unit reduction assay (FFURA) was used to evaluate
the in vitro anti-dengue virus activity of quercetin after viral adsorption. Foci of the non-treated infected cells (a) compared with foci in cells
treated with quercetin (50 μg/ml) postadsorption (b). Arrows indicate foci which are more diffused, less intensely stained and smaller than the
foci in non-treated cells.
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flavonoids as a group could consist of select compounds
that possesses inhibitory activities against DENV. To
investigate which of the many flavonoids could affect
DENV infection, in the present study, we examined the
potential effects of quercetin, naringin, hesperetin and
daidzein on dengue virus infection of Vero cells. Unlike
the previous studies which evaluated antiviral activity of
flavonoids only after adsorption of virus to the cells
[22,23], the present study evaluated antiviral activity by
different treatment procedures tailored to determine
prophylactic, post adsorption, continuous treatment and
direct virucidal activities of quercetin, naringin, daidzein
and hesperetin.
Our findings demonstrated that quercetin was the
only compound among all tested flavonoids that consis-
tently showed significant antiviral activity against
DENV-2 in Vero cells. Selectivity indices for quercetin
when the infected cells were treated or when uninfected
cells were treated continuously 5 h before infection until
4 days post-infection were 7.07 and 8.74, respectively.
The noted differences between SI values for quercetin
could be due to the intracellular accumulation of quer-
cetin during continuous treatment. A weak effect for
prophylactic activity of quercetin however, was also
observed. These findings suggest that the main anti-den-
gue activity of quercetin is likely due to its activity
against the different stages of intracellular replication of
DENV-2 instead of early stages of its replication cycle
such as virus attachment or entry. Although, no direct
virucidal activity or anti-attachment activity of quercetin
was observed in the present study, antiviral activity of
quercetin against human cytomegalovirus was reported
with IC50 = 3.2 μM [13]. Quercetin was also reported to
be effective against herpes viruses where it is more spe-
cific against HSV-1 with SI = 22 compared to HSV-2
with SI = 5.7 [11].
The mechanisms of how quercetin exerts its antiviral
effects are not known. However, the effects of other fla-
vonoids against cellular RNA polymerases and formation
of the complex with RNA have been reported suggesting
that quercetin could also affect the similar replication
enzymes [25,26]. Sylimarin, a flavonoid found effective
against hepatitis C virus (HCV), another member of fla-
viviridae family [27], inhibits virus replication by inhibit-
ing the activity of viral RNA polymerase. In our study,
results from the qRT-PCR supported the findings from
the viral foci reduction assays that quercetin inhibits
DENV-2 replication and the significant reduction in the
DENV specific RNA suggests that quercetin may also
target the virus replication machinery, namely by inhi-
biting the RNA polymerase.
Antiviral activity of naringin has been evaluated
against few herpesviruses and rotavirus but their
reported antiviral activities against HSV-1 and HSV-2
are inconclusive [12,17]. In addition it was reported that
naringin did not exhibit any antiviral activity against
another RNA virus, sindbis virus [14]. In the present
study, the only anti-dengue activity of this flavonoid was
demonstrated against adsorption and attachment of
virus to the Vero cells and based on its antiviral activity
(IC50 = 168.2 μg mL
-1) and its related selectivity index
(SI = 1.3), it may not be a good candidate for further
development as anti-dengue drug. Similarly, daidzein
activity against DENV-2 was not significant compared
to quercetin (SI = 1.03). Continuous treatment of the
infected Vero cells from 5 h before virus infection up to
4 days post infection did not improve its anti-dengue
activity significantly. This compound therefore, could
not be a suitable candidate for further development as
anti-dengue drug. Hesperetin, the other flavonoid evalu-
ated in our study, did not show no anti-dengue activity
in any stages of virus infection and replication processes
and this is despite the previously reported antiviral
activity of hesperetin against sindbis virus [14]. There-
fore, hesperetin is also not recommended for further
investigations for anti-dengue drug development. In all
our experiments, we showed that 0.5% of DMSO, the
highest concentration of solvent used in the bioflavonoid
treatment did not exhibit any antiviral activity against
DENV-2 and this eliminated any probable antiviral
activity from DMSO.
Findings from our study, suggest that there are select
flavonoids including quercetin and fisetin, which are
both flavonol, that exhibited significant DENV replica-
tion inhibition properties [28]. While the flavonoids in
general share common basic molecular base structure,
flavone (2-phenyl-1,4-benzopyrone), we showed here
that the flavanone, hesperetin, and flavanone glycoside,
naringin, showed no significant anti-DENV replication
activities. In addition, we had earlier shown that narin-
genin [28], another flavanone metabolized from naringin
and here, daidzein, an isoflavone also had no significant
DENV replication inhibition properties. While quercetin
was shown here to be effective in inhibiting DENV
replication, its glycoside form, rutin (quercetin-3-O-ruti-
noside) showed no significant inhibition properties [28].
These suggest that while flavonol could be the basic
molecule that possesses anti DENV replication proper-
ties, specific structural properties of the different flavo-
nol derivatives would have different effects on the
efficacy of the compounds against dengue.
The demonstration in vitro that flavonols including
quercetin and fisetin possess anti DENV replication
properties does not necessarily translate into immediate
use of these compounds as antivirals against DENV.
Further studies will be needed to demonstrate the anti-
viral activities of these compounds against different gen-
otypes of dengue virus and in appropriate animal model.
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There is also a need to address the issue of the low
bioavailability of quercetin especially for therapeutic use
[29-31]. Several strategies to increase the bioavailability
of quercetin that include using lipids and emulsifiers,
co-crystalization of quercetin or using ester-based pre-
cursors have been investigated [32-34]. The other topic
of research would be combination drug study. At its
current calculated IC50 values, the antiviral efficacy of
quercetin can be further improved possibly by combin-
ing it with other potential anti-dengue compounds. This
is exemplified in a study that reported the synergistic
effect of a- glucoside in combination with a standard
antiviral drug, ribavirin is effective against dengue infec-
tion [35].
Conclusions
In conclusion, the present study demonstrates that the
bioflavonoid quercetin exhibited significant anti DENV
replication properties. We further showed that quercetin
affects intracellular DENV virus replication but not the
DENV attachment and entry processes. These results
together with the earlier findings reporting the anti
DENV properties of fisetin, suggest that these flavonols
could be further investigated for their specific uses as
candidate anti-DENV therapeutics.
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